Related Experiment Video
Updated: Feb 26, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Therapeutic advances in monoclonal gammopathy-associated renal diseases]
Anne Boesch1, Michel Burnier2, Anne Cairoli3
1Service de médecine interne, CHUV, 1011 Lausanne.
Abstract:
During the last ten years, significant advances have been made in the field of monoclonal gammopathy-associated renal diseases. These have consisted in a better recognition of their pathological and clinical significations and correlation. Furthermore, therapeutic advances have allowed improving the prognosis of B-cell monoclonal proliferations and of the related renal complications. In the peculiar case of the multiple myeloma with severe renal failure requiring dialysis, one can now expect better survival and chance of recovering renal function.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chronic Kidney Disease III: Interprofessional Care
Therapeutic Drug Monitoring: Affecting Factors
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease IV: Nursing Management

